Holen Sie sich die Stockscreener-App
2.713
4.42%
0.113
Schlusskurs vom Vortag:
$2.60
Offen:
$2.6
24-Stunden-Volumen:
309.08K
Relative Volume:
0.44
Marktkapitalisierung:
$155.35M
Einnahmen:
$70.00M
Nettoeinkommen (Verlust:
$22.37M
KGV:
7.132
EPS:
0.3804
Netto-Cashflow:
$29.61M
1W Leistung:
-7.02%
1M Leistung:
+13.60%
6M Leistung:
-25.00%
1J Leistung:
+52.53%
1-Tages-Spanne:
$2.58
$2.77
1-Wochen-Bereich:
$2.535
$2.94
52-Wochen-Spanne:
$1.46
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Firmenname
Black Diamond Therapeutics Inc
Sektor
Branche
Telefon
617-417-5868
Adresse
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.711 | 148.98M | 70.00M | 22.37M | 29.61M | 0.3804 |
VRTX
Vertex Pharmaceuticals Inc
|
427.67 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.68 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.58 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.05 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.09 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-11-18 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-31 | Eingeleitet | Raymond James | Outperform |
| 2023-07-14 | Eingeleitet | Piper Sandler | Overweight |
| 2023-06-30 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-03-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-03-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-01-07 | Eingeleitet | Wedbush | Outperform |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-02-24 | Eingeleitet | Cowen | Outperform |
| 2020-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
Implied volatility surging for Black Diamond Therapeutics stock options - MSN
HC Wainwright Issues Positive Forecast for BDTX Earnings - MarketBeat
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
[ARS] Black Diamond Therapeutics, Inc. SEC Filing - Stock Titan
Black Diamond Therapeutics (BDTX) outlines 2026 virtual meeting and Say-on-Pay votes - Stock Titan
BDTX Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Given New $11.00 Price Target at BTIG Research - MarketBeat
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Zacks Investment Research
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Will Upcoming Catalysts Help Black Diamond Investors Breathe Easy? - RTTNews
Black Diamond stock: Weighing catalysts vs. concentration - MSN
Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy - MarketBeat
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize - TradingView
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Yahoo Finance
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks - TradingView
BlackDiamond (BDTX) Stock: Technical Momentum Review | Q4 2025: Earnings Fall ShortBuyback Report - Xã Châu Thành
BDTX (Black Diamond Therapeutics Inc.) shares rise nearly 8 percent even as fourth quarter 2025 earnings fall well below analyst estimates.Community Sell Signals - UBND thành phố Hải Phòng
Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting - Quiver Quantitative
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - ChartMill
Lung cancer drug data from Black Diamond gets ASCO oral slot - Stock Titan
BlackDiamond (BDTX) Stock Options Volume (Grinds Higher) 2026-04-20High Yield Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
BlackDiamond (BDTX) Stock: Why Day Traders Love It (+4.79%) 2026-04-18Social Momentum Signals - UBND thành phố Hải Phòng
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Black Diamond Sued Over Patented Cancer Drug Discovery Methods - Bloomberg Law News
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Yahoo Finance
BlackDiamond (BDTX) Stock Adds to Position (Buying Pressure) 2026-04-15Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Trading Action: Will Black Diamond Therapeutics Inc benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - baoquankhu1.vn
Volatility Watch: Will Black Diamond Therapeutics Inc benefit from AI trends2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts - National Today
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Market Fear: Does Black Diamond Therapeutics Inc outperform in volatile marketsGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Invesco Senior Loan Fund's Black Diamond Therapeutics Inc(BDTX) Holding History - GuruFocus
Investment Recap: How does Black Diamond Therapeutics Inc score in quality rankingsWeekly Investment Summary & Long-Term Safe Return Strategies - baoquankhu1.vn
Risk Recap: Is Black Diamond Therapeutics Inc part of any ETFDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
BDTX: Insights from Silevertinib Data on EGFR NSCLC Growth Potential - Bitget
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026 - TradingView
Black Diamond Stock: Weighing Catalysts vs. Concentration - Yahoo Finance
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside - TradingView
Finanzdaten der Black Diamond Therapeutics Inc-Aktie (BDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):